Octapharma (Switzerland)

Recent papers from Octapharma (Switzerland)

1. The association of estimated citrate load with frozen plasma versus four-factor prothrombin complex concentrate for coagulopathy after cardiac surgery: a post hoc exploratory analysis of the FARES-II randomised controlled trialBJA Open · 2026
2. Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: First results from wil-33Blood · 2025
3. Impact of secondary FVIII prophylaxis on joint bleeding and arthropathy in a Hemophilia A mouse model lacking inhibitor responseBlood · 2025
4. Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteinsResearch and Practice in Thrombosis and Haemostasis · 2025
5. NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre studyBMJ Open · 2025
6. A Randomized Placebo-Controlled Trial of the Efficacy and Tolerability of Etofenamate 70 mg Medicated Plaster for the Treatment of Pain in Acute Sprains, Strains or Bruises of the Soft Tissues Following Blunt TraumaPain and Therapy · 2025
7. von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case ReportTH Open · 2025
8. Potential military applications for a new freeze‐dried plasmaTransfusion · 2025
9. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative reviewTransfusion and Apheresis Science · 2025
10. Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac SurgeryJAMA · 2025
11. Protocol for a phase 3, randomised, active-control study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients requiring coagulation factor replacement: the LEX-211 (FARES-II) trialBMJ Open · 2024
12. von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand diseaseBlood Advances · 2024
13. Simoctocog alfa (Nuwiq ® ) in children: early steps in life’s journey for people with severe hemophilia ATherapeutic Advances in Hematology · 2024
14. Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)Therapeutic Advances in Hematology · 2024
15. Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia AHaemophilia · 2023
16. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM studyEClinicalMedicine · 2023
17. Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 studyHealth Science Reports · 2023
18. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect studyEuropean Journal Of Haematology · 2023
19. Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA‐02 and FORMA‐04 clinical trialsTransfusion · 2022
20. Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) StudyTH Open · 2022